FDA: Unacceptable NDMA Levels in Diabetes Drug; Cushing Disease Tx Available

Inbox

x

MPR Daily Dose <editor@email.empr.com> Unsubscribe

3:03 AM (10 hours ago)

to me

If you are having trouble viewing this email, click here.

MUST READS FDA: Unacceptable NDMA Levels Identified in Certain Metformin ER Products Opdivo Plus Yervoy With Limited Chemotherapy Approved for First-Line Metastatic or Recurrent NSCLC Isturisa Now Available for Treatment of Patients With Cushing Disease Ofatumumab Bests Teriflunomide in Halting Disease Activity in MS Patients Mepolizumab Gets Priority Review for Hypereosinophilic Syndrome MPR Weekly Dose Podcast MPR Weekly Dose Podcast Episode 36 COVID-19 Resource Center CME/CE Spotlight Improved Outcomes for Naïve & Heavily Treatment—Experienced HIV Patients AMA PRA Category 1 Credit(s)TM, CE for Pharmacists CLICK HERE FOR A FULL LIST OF COURSES CE/CME Powered By myCME